RESEARCH TRIANGLE PARK – Jacob Jacobsen, a co-founder of Evecxia Therapeutics along with the late Marc Caron and a former Duke University professor, is now the firm’s chief executive officer.
The company announced Thursday Jacobsen was replacing Joseph Patti who left the firm to “pursue other interests.”
Earlier, Evecxia, a clinical-stage pharmaceutical company co-founded by two Duke neuro-psychopharmacologists, secured $2.4M from Miami-based Collage Venture Partners, according to an SEC filing.
On Duke’s Translation & Commercialization website, Evecxia is described as a “singular mission” to develop and commercialize a treatment for depressed patients who do not respond to conventional antidepressants.
“We are excited to appoint Jacob as Evecxia’s next CEO to advance Evecxia’s pipeline of two Phase 2-ready drug candidates, EVX-101 and EVX-301, to help improve the lives of those suffering from disabling neuropsychatric disorders,” said John Kaiser, executive chairman of the firm’s board of directors.